Shots:
- The US FDA has accepted NDA of relacorilant for the treatment of Pt-resistant ovarian cancer (PDUFA: Jul 11, 2026)
- NDA was supported by P-III (ROSELLA) & P-II trials, where relacorilant + nab-paclitaxel demonstrated improved PFS & OS compared to nab-paclitaxel monotx., with no need for biomarker selection & favorable safety
- Additionally, relacorilant (GR antagonist) received ODD from both FDA & EMA to treat ovarian cancer, with FDA granting PDUFA data of Dec 30, 2025, for the treatment of pts with hypercortisolism
Ref: Corcept Therapeutics | Image: Corcept Therapeutics | Press Release
Related News:- Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
